science3 distinct publishers
Pancreatic cancer's undruggable target falls, and the median moves from 6.7 to 13.2 months
The FDA cleared daraxonrasib on Aug. 26 for patients whose chemotherapy has already failed. The median gain is 6.5 months, and the price has not been disclosed.
Perspective Coverage
3 publishers- Builder
- Builder 35%
- Operator
- Operator 42%
- Investor
- Investor 23%
Reality
- Evidence78
- Adoption25
- Hype gap+18